Table 1. Characteristics of included studies.

Study, year and country	Design	Location of lesions	Inclusion criteria	Exclusion criteria	n	Males	Age, years	ROSE	Suction	Fanning	Follow-up
Bang, 2012 (USA) 19	Randomized trial	Pancreas	All patients referred for solid pancreatic lesions on CT scan	Cystic pancreatic lesions, coagulopathy, lesions not seen on EUS	56	31	65	Yes	No	Yes	6 months
Hucl, 2013 (India) 20	Prospective	Pancreas & lymph nodes	Consecutive patients with pancreatic masses or peri-intestinal nodes	Lesion not seen on EUS	145	80	48	No	Yes	No	6 months
Witt, 2013 (USA) 21	Retrospective	Pancreas, gastric, mediastinal and pelvic nodes	First 18 patients undergoing EUS guided FNB for various lesions. Site matched controls undergoing EUS-FNA	NR	36	NR	NR	Yes	Yes	No	3.3 months
Kim, 2014 (Korea) 22	Randomized trial	Subepithelial lesions	Hypoechoic mass in submucosa and/or proper muscle layers, > 2 cm in size	Tumors not located in submucosa and/or proper muscle layers, cystic lesion, overlying vessel, platelet < 50 000, PT > 50 %, lipoma on EUS	22	10	56.3	No	Yes	No	NR
Vanbiervliet, 2014 (France) 23	Randomized trial	Pancreas	Pancreatic mass on CT scan, dilated CBD and or dilated PD	Cystic lesions, uncorrectable coagulopathy, pregnancy	80	49	67.1	No	Yes	Yes	6.4 months
Lee, 2014 (Korea) 24	Randomized trial	Pancreas	Solid pancreatic mass on CT or MRI, age > 18 years	Cystic mass, INR > 1.5, platelets < 80 000	116	77	64.9	Yes	Yes	No	6 months
Strand, 2014 (USA) 25	Prospective	Pancreas	Age 18 – 90 years, solid pancreatic mass on CT scan	Cystic lesion, no mass seen on EUS, uncorrectable coagulopathy	32	13	67.7	Yes	Yes	No	NR
Lin, 2014 (USA) 26	Prospective	Pancreas, lymph nodes, gastric, mediastinal nodes, liver lesions	All patients referred for EUS guided biopsy underwent both FNA and FNB	Core biopsy not performed if cystic lesions, < 1 cm lesion, overlying vascular structures precluding biopsy	26	25	66.8	Yes	Yes	NR	12 months
Mavrogenis, 2015 (Belgium) 27	Prospective	Pancreas, lymph nodes	All patients > 18 years old with pancreatic lesions or lymphadenopathy referred for EUS sampling	Cystic lesion, age < 18 years, pregnancy, INR > 1.5, platelet < 50 000	28	9	69 (med)	No	Yes	No	7 months
Berzosa, 2015 (USA) 28	Retrospective	Pancreas	Patients with solid pancreatic lesions on CT scan undergoing EUS sampling	NR	61	35	61	Yes	NR	No	6 months
Alatawi, 2015 (France) 29	Prospective	Pancreas	Solid pancreatic tumors > 2 cm size on CT or MRI	Cystic lesions, patients with biliary stents	100	63	68.4	No	Yes	Yes	NR
Yang, 2015 (Korea) 30	Retrospective	Pancreas	Solid pancreatic lesions in consecutive patients undergoing EUS	NR	76	35	62.4	No	Yes	Yes	6 months
Dwyer, 2016 (USA) 31	Retrospective	Pancreas, gastric and colon submucosal mass, pelvic and perirectal masses	All EUS guided biopsies of solid intraabdominal masses	NR	58	32	63	Yes	NR	NR	NR
Kandel, 2016 (USA) 32	Retrospective	Pancreas, liver, subepithelial lesions, lymph nodes	Consecutive patients undergoing EUS-FNB were matched with random controls undergoing EUS-FNA ratio of 1:3	NR	156	84	66	Yes	NR	NR	NR
Rodrigues-Pinto, 2016 (USA) 33	Retrospective	Pancreas, lymph nodes, submucosal lesions	NR	NR	33	15	65	Yes	Yes	NR	NR

NR, not reported; CBD, common bile duct; PD, pancreatic duct; INR, international normalized ratio; PT, prothrombin time; EUS, endoscopic ultrasound; FNB, fine-needle biopsy; FNA, fine-needle aspiration; ROSE, rapid onsite evaluation.